These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 15010143)

  • 41. Mechanisms by which moisture generates cocrystals.
    Jayasankar A; Good DJ; Rodríguez-Hornedo N
    Mol Pharm; 2007; 4(3):360-72. PubMed ID: 17488034
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process.
    Park HJ; Kim MS; Lee S; Kim JS; Woo JS; Park JS; Hwang SJ
    Int J Pharm; 2007 Jan; 328(2):152-60. PubMed ID: 16959448
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Crystal forms of LY334370 HCl: isolation, solid-state characterization, and physicochemical properties.
    Reutzel-Edens SM; Kleemann RL; Lewellen PL; Borghese AL; Antoine LJ
    J Pharm Sci; 2003 Jun; 92(6):1196-205. PubMed ID: 12761809
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Determination of hydrate transition temperature using transformation kinetics obtained by Raman spectroscopy.
    Wikström H; Kakidas C; Taylor LS
    J Pharm Biomed Anal; 2009 Feb; 49(2):247-52. PubMed ID: 19112003
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Medium-throughput hydrate screening using the Crystal 16™.
    Sistla A; Wu Y; Khamphavong P; Liu J
    Pharm Dev Technol; 2011 Apr; 16(2):102-9. PubMed ID: 20088649
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stable-form screening: overcoming trace impurities that inhibit solution-mediated phase transformation to the stable polymorph of sulfamerazine.
    Gong Y; Collman BM; Mehrens SM; Lu E; Miller JM; Blackburn A; Grant DJ
    J Pharm Sci; 2008 Jun; 97(6):2130-44. PubMed ID: 17879974
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Physical characterization of anhydrous and hydrous forms of the hydrochloride salt of BVT.5182 a novel 5-HT(6) receptor antagonist.
    Hugerth A; Brisander M; Wrange U; Kritikos M; Norrlind B; Svensson M; Bisrat M; Ostelius J
    Drug Dev Ind Pharm; 2006 Feb; 32(2):185-96. PubMed ID: 16537199
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Interactions of water with the surfaces of crystal polymorphs.
    Carvajal MT; Staniforth JN
    Int J Pharm; 2006 Jan; 307(2):216-24. PubMed ID: 16298501
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Simultaneous measurement of liquid-phase and solid-phase transformation kinetics in rotating disc and channel flow cell dissolution devices.
    Lehto P; Aaltonen J; Niemelä P; Rantanen J; Hirvonen J; Tanninen VP; Peltonen L
    Int J Pharm; 2008 Nov; 363(1-2):66-72. PubMed ID: 18675891
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Characterisation of blends of paracetamol and citric acid.
    Hoppu P; Jouppila K; Rantanen J; Schantz S; Juppo AM
    J Pharm Pharmacol; 2007 Mar; 59(3):373-81. PubMed ID: 17331340
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Influence of temperature on solvent-mediated anhydrate-to-hydrate transformation kinetics.
    Qu H; Munk T; Cornett C; Wu JX; Bøtker JP; Christensen LP; Rantanen J; Tian F
    Pharm Res; 2011 Feb; 28(2):364-73. PubMed ID: 20886266
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Influence of particle size and preparation methods on the physical and chemical stability of amorphous simvastatin.
    Zhang F; Aaltonen J; Tian F; Saville DJ; Rades T
    Eur J Pharm Biopharm; 2009 Jan; 71(1):64-70. PubMed ID: 18703139
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques.
    Kawashima Y; Niwa T; Takeuchi H; Hino T; Itoh Y; Furuyama S
    J Pharm Sci; 1991 May; 80(5):472-8. PubMed ID: 1715401
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Solubility of molecular crystals: polymorphism in the light of solubility theory.
    Bennema P; van Eupen J; van der Wolf BM; Los JH; Meekes H
    Int J Pharm; 2008 Mar; 351(1-2):74-91. PubMed ID: 17980982
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cefdinir: A comparative study of anhydrous vs. monohydrate form. Microstructure and tabletting behaviour.
    Cabri W; Ghetti P; Alpegiani M; Pozzi G; Justo-Erbez A; Pérez-Martínez JI; Villalón-Rubio R; Monedero-Perales MC; Muñoz-Ruiz A
    Eur J Pharm Biopharm; 2006 Oct; 64(2):212-21. PubMed ID: 16846727
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Influence of the solid form of siramesine hydrochloride on its behavior in aqueous environments.
    Zimmermann A; Tian F; Lopez de Diego H; Ringkjøbing Elema M; Rantanen J; Müllertz A; Hovgaard L
    Pharm Res; 2009 Apr; 26(4):846-54. PubMed ID: 19005740
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A study of the differences between two amorphous spray-dried samples of cefditoren pivoxil which exhibited different physical stabilities.
    Ohta M; Buckton G
    Int J Pharm; 2005 Jan; 289(1-2):31-8. PubMed ID: 15652196
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of environmental humidity on the transformation pathway of nitrofurantoin modifications during grinding and the physicochemical properties of ground products.
    Otsuka M; Matsuda Y
    J Pharm Pharmacol; 1993 May; 45(5):406-13. PubMed ID: 8099957
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Physical and chemical characteristics of a new cefazolin sodium hydrate crystal].
    Hu CQ; Yin LH; Liang YN
    Yao Xue Xue Bao; 2008 Aug; 43(8):868-72. PubMed ID: 18956782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Crystal forms of tolbutamide from acetonitrile and 1-octanol: effect of solvent, humidity and compression pressure.
    Chakravarty P; Alexander KS; Riga AT; Chatterjee K
    Int J Pharm; 2005 Jan; 288(2):335-48. PubMed ID: 15620874
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.